Skip to content
10-K

Annual Report

Calidi Biotherapeutics, Inc. CLDI CLDWW

0001493152-26-013242

← back to feed
Filed
Mar 27, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 20, 2026 10.9M sh
Shares Diluted FY 2025 · Dec 31, 2025 4.3K sh
Shares Diluted restated FY 2025 · Dec 31, 2024 667 sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$21.29M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$19.69M
Long Term Debt FY 2025 · Dec 31, 2025 $600K
Long Term Debt FY 2025 · Dec 31, 2024 $600K
Short Term Debt FY 2025 · Dec 31, 2025 $90K
Short Term Debt FY 2025 · Dec 31, 2024 $3.22M
Stockholders Equity FY 2025 · Dec 31, 2025 $3.76M
Stockholders Equity FY 2025 · Dec 31, 2024 $1.53M
Current Liabilities FY 2025 · Dec 31, 2025 $3.94M
Current Liabilities FY 2025 · Dec 31, 2024 $9.5M
Total Liabilities FY 2025 · Dec 31, 2025 $5.1M
Total Liabilities FY 2025 · Dec 31, 2024 $12.21M
Current Assets FY 2025 · Dec 31, 2025 $6.26M
Current Assets FY 2025 · Dec 31, 2024 $10.23M
Total Assets FY 2025 · Dec 31, 2025 $8.86M
Total Assets FY 2025 · Dec 31, 2024 $14.18M
Eps Diluted FY 2025 · Dec 31, 2025 −$5.95
Eps Diluted restated FY 2025 · Dec 31, 2024 −$35.70
Eps Basic FY 2025 · Dec 31, 2025 −$5.95
Eps Basic restated FY 2025 · Dec 31, 2024 −$35.70
Sga Expense FY 2025 · Dec 31, 2025 $10.5M
Sga Expense FY 2025 · Dec 31, 2024 $12.9M
Rd Expense FY 2025 · Dec 31, 2025 $9.74M
Rd Expense FY 2025 · Dec 31, 2024 $8.88M
Net Income FY 2025 · Dec 31, 2025 −$19.91M
Net Income FY 2025 · Dec 31, 2024 −$22.14M
Operating Income FY 2025 · Dec 31, 2025 −$20.24M
Operating Income FY 2025 · Dec 31, 2024 −$21.78M